Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD - Seite 2

_____________________________

¹ Alzheimer's Association. (2023). Alzheimer's Disease Facts and Figures. Retrieved from https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf

Notably, although the trial was not powered for finding efficacy on neuropsychological scales, the ABvac40-treated group exhibited as much as a 38% reduction in disease progression, as reflected by the Mini-Mental State Examination (MMSE) score, suggesting ABvac40’s potential efficacy in addressing the cognitive decline associated with AD.

Other neuropsychological tests, such as the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) or the Trial Making Test (TMT), showed favorable results on ABvac40 versus the placebo group. Global or functional scales did not show differences of ABvac40 group vs placebo group. In addition, volumetric magnetic resonance imaging showed a lesser increase in whole brain atrophy in the ABvac40 group vs placebo.

"We are pleased to report final positive results from the Phase 2 study of ABvac40, including a robust immune response with some significant reduction in disease progression, all with a favorable safety profile,” said Jose Terencio, Ph.D., Araclon chief executive officer and vice president of Grifols Innovation and New Technologies. “Previous vaccines in development for AD faced setbacks due to harmful meningoencephalitis side effects. The results reported for ABvac40 to date validate its clinical potential, positioning it as promising therapeutic candidate for early AD treatment. We look forward to evaluating next steps for this program.”

Mercè Boada Rovira, M.D., Ph.D., co-founder and medical director of the Ace Alzheimer Center in Barcelona and principal investigator of the study, added, “Despite recent treatment developments, there is a large unmet need for disease-modifying therapies for the increasingly growing population of AD patients, particularly in the management of early stages of the disease. By specifically targeting the Aβ40 peptide, ABvac40 is tapping into a central mechanism believed to drive cognitive decline with potential to alter the course of disease.”

About the Phase 2 trial
ABvac40 was studied in a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial (NCT03461276) conducted across 23 sites in the EU, to investigate safety, tolerability and immunogenicity of repeated subcutaneous injections of ABvac40 in patients with amnestic mild cognitive impairment (a-MCI) or very mild Alzheimer’s Disease (AD). The study was divided into two parts with a total enrollment of 134 patients. In Part-A (18-24 months), patients were randomized to receive a total of six doses, including one monthly single-dose injection of ABvac40 or placebo for the first five months, followed by a delayed booster of ABvac40 or placebo at month 10. Part-B (18 months) was an extension study with cross-over of treatment from Part-A, in which placebo patients at Part-A received ABvac40, and ABvac40-treated patients received placebo and a booster of ABvac40. Primary endpoints were immunogenicity, safety, and tolerability. Safety was assessed as the incidence of treatment-emergent adverse events (TEAEs), serious TEAEs (TESAEs) and TESAEs of special interest, including sulcal effusion and parenchymal edema (ARIA-E), microhemorrhages hemosiderin and deposition (ARIA-H) and aseptic meningo-encephalo-myelitis. Secondary endpoints, assessed at several time points across Part-A, were neuropsychological tests, AD biomarkers in cerebrospinal fluid, cortical fibrillary amyloid deposition, and brain volumetric analysis.